Document is current
Any future updates will be listed below
-
Authors
Chu, Danny Hoi Tsun
Schalkamp, Ann-Kathrin
Rudrapatna, Vivek A.
- License Information
-
More Information
Article History
Received: 25 July 2025
Accepted: 2 March 2026
First Online: 24 March 2026
Declarations
:
: Vivek A. Rudrapatna's research is funded by grants to UCSF from the following for-profit entities: BeOne Medicines Ltd, Johnson and Johnson, Takeda, Blueprint Medicines, Merck, Mitsubishi Tanabe, Genentech, and Stryker. He is a scientific advisor to ZebraMD, and Data Unite. He has previously received payment from Natera and Ironwood. The remaining authors disclose no conflicts. The authors declare that no actual competing interests exist.
: This study complies with all relevant ethical regulations and was approved by Institutional Review Board of University of California, San Francisco, with approval reference #18-24588.
